MetaVia Inc. (MTVA) stock
MTVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.30+0.00 (0.00%)
Close on Nov 13, 2026Market cap $8.56MP/E –Yield –
MetaVia EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
MetaVia's EPS for the twelve months ending Sep 30, 2025 was -$13.87. For fiscal 2025 it was -$7.35. The highest annual figure on record is -$7.35 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.35 | – |
| FY2024 | Dec 31, 2024 | -$39.13 | – |
| FY2023 | Dec 31, 2023 | -$27.06 | – |
| FY2022 | Dec 31, 2022 | -$477.62 | – |
| FY2021 | Dec 31, 2021 | -$1743.28 | – |
| FY2020 | Dec 31, 2020 | -$4831.20 | – |
| FY2019 | Dec 31, 2019 | -$10771.20 | – |
| FY2018 | Dec 31, 2018 | -$9636.00 | – |
| FY2017 | Dec 31, 2017 | -$23449.80 | – |
| FY2016 | Dec 31, 2016 | -$18658.20 | – |
| FY2015 | Dec 31, 2015 | -$32960.40 | – |
| FY2014 | Dec 31, 2014 | -$1524.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.69 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.90 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.79 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.52 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.87 | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.93 | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.55 | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.05 | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.35 | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.52 | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.48 | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.25 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.65 | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.61 | – |
| Q3 FY2022 | Sep 30, 2022 | -$308.00 | – |
| Q2 FY2022 | Jun 30, 2022 | -$327.36 | – |
| Q1 FY2022 | Mar 31, 2022 | -$285.12 | – |
| Q4 FY2021 | Dec 31, 2021 | -$456.75 | – |
| Q3 FY2021 | Sep 30, 2021 | -$410.08 | – |
| Q2 FY2021 | Jun 30, 2021 | -$475.20 | – |
| Q1 FY2021 | Mar 31, 2021 | -$396.00 | – |
| Q4 FY2020 | Dec 31, 2020 | -$3128.61 | – |
| Q3 FY2020 | Sep 30, 2020 | -$501.60 | – |
| Q2 FY2020 | Jun 30, 2020 | -$396.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$792.00 | – |
| Q4 FY2019 | Dec 31, 2019 | -$6516.38 | – |
| Q3 FY2019 | Sep 30, 2019 | -$1848.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$976.80 | – |
| Q1 FY2019 | Mar 31, 2019 | -$1267.20 | – |
| Q4 FY2018 | Dec 31, 2018 | -$1887.60 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3121.80 | – |
| Q2 FY2018 | Jun 30, 2018 | -$3412.20 | – |
| Q1 FY2018 | Mar 31, 2018 | -$4210.80 | – |
| Q4 FY2017 | Dec 31, 2017 | -$4573.80 | -180.8% |
| Q3 FY2017 | Sep 30, 2017 | -$5953.20 | – |
| Q2 FY2017 | Jun 30, 2017 | -$7187.40 | – |
| Q1 FY2017 | Mar 31, 2017 | -$5735.40 | – |
| Q4 FY2016 | Dec 31, 2016 | $5662.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?